Form 4: Biodesix Director Lawrence T. Kennedy Jr. Acquires 35,000 Shares

Director Lawrence T. Kennedy Jr. of Biodesix Inc. purchased 35,000 shares of common stock at a weighted average price of $1.1589 on November 21, 2024.

Summary

• Lawrence T. Kennedy Jr., a director at Biodesix Inc., acquired 35,000 shares of the company's common stock on November 21, 2024.
• The shares were purchased at a weighted average price of $1.1589 per share.
• The transactions were made through a series of purchases with prices ranging from $1.155 to $1.1602.
• Following the transaction, Mr. Kennedy's indirect holdings include 10,411,024 shares through a revocable trust, 12,267,873 shares through a perpetuity trust, and 2,775,386 shares through KFDI-B LLC.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While a director buying shares is generally positive, the scale of the purchase is not significant enough to indicate a strong positive sentiment.

Positives

• A director's purchase of shares can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transaction is a relatively small purchase compared to the total shares held by the director, and is not unusual for directors of publicly traded companies.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment due to the director's increased investment.

Key Dates

Keywords

Biodesix, BDSX, Lawrence T. Kennedy Jr., stock purchase, insider trading, Form 4, director, share acquisition